Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265270 | 1.00 | — | — | |
| SCHEMBL4257324 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4262601 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4261755 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4258055 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4261584 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4265264 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4254125 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4260877 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT | |
| SCHEMBL4258815 | 1.00 | KMT2A (0.36) | KMT2ACA1CA2CA4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084625-B2 | Crosslinking agent, crosslinking method, method of controlling gene expression, and method of examining gene function | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023140-A1 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION | DCLRE1A, RNGTT, NSUN2 | KMT2A 1462/4885CA1 3648/4885CA2 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.